Post – Event Press Release 4th Annual Conference “Lung Cancer in the Spotlight: New Perspectives and Challenges”

Prevention, Innovation, Collaboration and Holistic Care: A New Horizon in the Fight Against Lung Cancer

Athens, December 3, 2024 – 65 speakers and commentators – representatives of bodies from the scientific, academic, and research community of Greece and abroad, representatives of the Church of Greece and the Greek State, patients and the pharmaceutical industry – were hosted at the 4th Annual Conference of FairLife Lung Cancer Care , entitled: “Lung Cancer in the Spotlight: New Perspectives and Challenges”.

The conference, which took place on Wednesday, November 27, at ATRAKTOS Venue, was attended in person and online by 3,998 people at the culmination of FairLife LCC’s activities for November, lung cancer awareness month.

Here you can watch the conference.

The conference was held under the auspices of: Holy Archdiocese of Athens and All Greece, Hellenic Society of Medical Oncology (HeSMO), Hellenic Thoracic Society (HTS), Hellenic Society of Radiation Oncology (HESRO), Hellenic Radiological Society (HELRAD), Hellenic Association of Lung Cancer (HeALC), Hellenic Society of Pathological Anatomy, Hellenic Society of Cardiothoracic and Vascular Surgeons, Hellenic Nurses Association, ΗWomen for Oncology (W4O-Hellas), Hellenic Federation of Cancer (ELLOK) Foundation for Cancer Research (HFCR), International Association for the Study of Lung Cancer (IASLC), Global Lung Cancer Coalition (GLCC), European Lung Foundation (ELF), Lung Cancer Europe (LuCE), Lung Cancer Awareness Month Coalition (LCAM), Hellenic Association of Pharmaceutical Companies (SFEE), PhRMA Innovation Forum (PIF).

Kindly supported by:

• Distinguished Sponsor: MSD
• Major Sponsors: AstraZeneca, Genesis Pharma, Roche.
• Sponsors: BMS, GSK, Gilead, Johnson & Johnson, Pfizer, PharmaServe Lilly, ISTODIEREYNITIKI
• Communication Supporters: ΑCS, CATALYTICA, ETS Events and Travel Solutions & Live MeD, INNEWS, REPUTATION UNIQUE, WASP Studio.

The event was moderated and presented by journalist Elena Papadimitriou.

The individual sections were moderated by Ms. Evi Hatziandreou, MD, DrPH, Dr. of Public Health, Harvard University, Vice President of FairLife LCC, and Mr. Giorgos Kapetanakis, President of the Hellenic Federation of Cancer (ELLOK).

Prevention and Early Diagnosis

Lung cancer prevention and early diagnosis face significant challenges in Greece, due to the delay in the inclusion of screening in the National Prevention Plan, inequalities in access to treatments, and the stigma of the disease.

The conference emphasized the need for targeted steps, such as the State increasing awareness about prevention, equal access to treatment, improving infrastructure, strengthening social awareness on screening, and supporting patients with knowledge and personalized holistic care.

The implementation of the lung cancer screening program, using low-dose CT scans (LDCT) in high-risk individuals and linking them to smoking cessation clinics, was considered imperative and expected, especially after the filing (in 2023) of the study with guidelines (Lung Cancer Screening-PEKP) at the Ministry of Health, the National Public Health Committee and the National Public Health Organization.

The need to strengthen Primary Health Care as a central pillar of prevention and holistic care was underlined.

At the same time, vaccinations for vulnerable groups were mentioned as vital, as well as the cooperation of the State and patient associations to change the culture of prevention and awareness-raising actions for the protection of socially vulnerable groups.

With the cooperation of bodies, the training of health professionals, the promotion of a culture of prevention, the investment in the new generation for sustainable changes and the development of research, a future with early diagnosis, accessible treatments and specialized care for all is visible.

Diagnostic Procedure & Biomarker Testing

The new, 9th edition of the TNM staging system for lung cancer, (2025), is expected to improve prognosis and offer more treatment options.

The key role of bronchoscopy procedures and artificial intelligence in diagnosing and improving the accuracy of biopsies was highlighted.

Molecular testing has emerged as a key tool of personalized treatment, and of the new era in oncology, with the urgent need to reimburse biomarkers from the State.

The need for a unified database for the reliable interpretation of the massive parallel sequencing results (NGS) was emphasized, while implementing the Molecular Oncology Council was deemed necessary to ensure equal access to innovative treatments.

Collaboration and innovation were identified as key pillars of holistic lung cancer treatment. The role of the pharmaceutical industry has appeared significant, with investments in prevention, research and development, as well as partnerships for patient support and awareness.

Lung cancer management

Modern lung cancer management requires multidisciplinary cooperation and personalized treatments, with an emphasis on the use of molecular biomarkers and innovative approaches such as immunotherapy, in both early and metastatic disease.

The restructuring of the Oncology Council was deemed necessary, as it improves diagnosis and treatment and at the same time it provides economic benefits to the health system.

The developments in thoracic surgery and radiotherapy with the use of stereotactic radiosurgery offering new treatment options, are important, especially in cases where surgical procedure is not an option.

The need for active participation of the patient in the course of treatment was highlighted, with the caregivers having a pivotal role in their support.

The need for ongoing training of doctors and improvement of medical infrastructure was recognized, and it was highlighted that the State must boost funding and improve policies on rebates and criteria for innovation in healthcare.

New data was presented about the ALK mutation which concerns a small percentage of patients but has led to significant progress thanks to third generation ALK inhibitors, while the prognosis of patients with EGFR mutations appears improved.

In the area of the rarest biomarkers, such as ROS1, NTRK, RET, BRAF, KRAS, and HER2, the significance of targeted treatment in in the front line was highlighted, emphasizing the encouraging response rates of approved molecules and the necessity of the patient participation in clinical studies to draw sound conclusions.

The value of clinical studies

 The value of clinical studies in oncology was considered decisive for the progress of science and treatment and free access to innovation.

The challenges mentioned were the limited number of clinical studies conducted in Greece compared to other countries, the difficulty in recruiting patients, due to lack of awareness and fear, the inequalities of access to clinical studies, and the insufficient funding of clinical research in Greece.The new European regulation to ensure transparency and cooperation in the field of clinical studies was presented on a positive note.The contribution of the pharmaceutical industry in the clinical studies appeared significant, with investments covering over 60% of the global spending on the development of new drugs. In conclusion, the need for greater support and collaboration in the area of clinical studies in Greece was emphasized, aiming to improve patient access to new treatments and foster innovation in oncology.

 

Holistic care

 Lung cancer treatment requires a holistic and human-centered approach.

Pain, recognized as an independent disease, necessitates a timely and organized inclusion of palliative care in the health system. However, in Greece, a notable delay is observed with gaps being filled primarily by associations and organizations, which highlights the need for political will to act.The multidisciplinary approach and the Patient-driven care model were highlighted as the epitome of holistic care. The importance of psychological support in maintaining patients’ mental health was highlighted. The training in comprehensive oncology care, the integration of alternative treatments, and the implementation of lifestyle medicine, with good nutrition and exercise were deemed necessary for the improvement of patients’ quality of life. Lastly, the importance of awareness on guilt and stigma created by lung cancer was pointed out, and the social and scientific mobilisation for the effective care of the people who are ill.

Common approach of the pharmaceutical industry

 The representatives of the pharmaceutical industry highlighted the need to focus on the patients’ quality of life, expressing their concern for the adverse environment in Greece regarding the equal access to innovative treatments. The importance of collaboration between the pharmaceutical industry and the bodies involved was highlighted, for the support of clinical studies as well as the development of new drugs. The significant contribution of the pharmaceutical sector to lung cancer treatment with proposals and initiatives was recognized. Lastly, the sector focused on the need to draw up a national action plan for holistic lung cancer treatment, for the benefit of the patients and the National Health System.

Here  you can download the photographic material of the Conference.

 

Detailed Presentation

 The President of FairLife Lung Cancer Care, Ms. Korina Pateli Bell, launched the conference, referring to the challenges that persist, such as the delay in the integration of screening in the National Prevention Plan, the inequalities in access to treatments, the patients’ financial burden and the disease-related stigma. “Lung cancer is a strong opponent but not invincible! This conference the is proof that together we can change lives.” she stressed, pointing out the need for continuous progress in prevention, diagnosis, innovative treatments, and patients’ holistic care.

 Bishop of Thespies, Mr. Pavlos, Representative of His Beatitude, the Archbishop of Athens and All Greece Ieronymos II, highlighted the multifaceted problems created by cancer and pointed out the need for awareness by the State on prevention, treatment, and improvement of infrastructure, and the importance of social awareness for screening and the avoidance of harmful habits.

In his address, Mr. Adonis Georgiadis, Minister of Health, referred to the State’s significant interest and intent regarding the integration of lung cancer screening into the National Prevention Plan.

The Deputy Minister of Health, Mr. Marios Themistokleous, highlighted the government’s efforts aimed at improving patients’ quality of life, specifically mentioning the establishment of new oncology centers, the home health services programs, the major digital upgrade, the establishment of a committee on palliative care, and improving access to innovative treatments. At the same time, he emphasized prevention and early diagnosis as key tools for effectively tackling the disease.

Dr. Zenia Saridaki, (MD, PhD), Medical Oncologist, President of the Hellenic Society of Medical Oncologists (HeSMO), Director of the 1st Oncology Clinic at Metropolitan Hospital, Athens, and Scientific Director of the Oncology Department of “Asklepios Diagnosis”, Heraklion, Crete, spoke about the progress of lung cancer research and the importance of prevention and early diagnosis in building a future of health and hope. She underlined that HeSMO is always supportive of visionary individuals and expressed the wish for the coverage of biomarkers, Next Generation Sequencing (NGS), and the implementation of lung cancer screening in Greece to become a reality.

“The life expectancy of a lung cancer patient depends more on their postal code than on their genetic code due to inequalitities in prevention and access to therapies,” stated Mr. Konstantinos N. Syrigos, Professor of Internal Medicine & Oncology, Medical School of the National and Kapodistrian University of Athens (NKUA), Director of the 3rd Department of Internal Medicine and Laboratory, Medical School, NKUA, and President of the Hellenic Society for the Study of Lung Cancer (HSSLC). Mr. Syrigos discussed the link between lung cancer and smoking, which is often prevalent among individuals belonging to the socioeconomic margin of society. He characterized awareness campaigns as a safety net for these individuals and for society as a whole.

Dr. Karen Kelly (MD), CEO of IASLC and Professor Emeritus at the University of California, Davis, emphasized the importance of collaboration among patients, caregivers, scientists, and healthcare professionals for the treatment of the disease. She stressed the significance of prevention, early diagnosis, and holistic care, as well as of empowering patients with knowledge and tools. Finally, she closed with optimism for “a future where early diagnosis will be the norm, treatments will be accessible to all patients worldwide, and clinical studies and research will continue to develop.”

“Anyone with lungs can develop the disease,” reminded Ms. Debra Montague, Vice President of LUCE and Chair of ALK UK, in her address, highlighting that lung cancer comprises many different diseases. She sent a strong message against the stigma of the disease and emphasized the importance of information and awareness of society.

The introductory section of the Conference featured a speech by Dr. Mina Gaga, MD, PhD, FERS, FCCP, Pulmonologist, former Deputy Minister of Health, Director of the 1st Respiratory Medicine, Department at Hygeia Hospital, and Member of the Standing Committee of the World Health Organization (WHO), Regional committee for Europe. Presenting the unfavorable image of lung cancer in Europe and Greece, Dr. Gaga spoke about the need for a modern treatment of the disease based on accurate information, primary, secondary, and tertiary prevention, early diagnosis, personalized treatment, holistic support for patients and their families, and ongoing care provided by a specialized team. She pointed out the disparities in the quality of healthcare services among European countries and expressed her concerns about the limited practical implementation of oncology councils in Greece despite the existing legal framework. “Effective health systems, quality services, respect for patients, and proper organization are needed to build trust in the health system,” she summarized.

The actor and director Mr. Giorgos Karamichos delivered an optimistic message on the importance of lung cancer prevention and early diagnosis, addressing the conference audience from the United States. Mr. Karamichos shared his personal experience with the disease, referring to its accidental detection at an early stage and the role of early diagnosis in his effective treatment while avoiding painful and complex procedures. At the same time, he highlighted citizens’ responsibility in prevention and called on the state to establish annual screenings for high-risk groups, emphasizing the benefits in terms of saving lives and financially.

 

Culture of prevention, political will & collaboration: the key to saving lives from lung cancer

” In Europe, the 3^rd ranked death that can be prevented is lung cancer with a percentage of 16%, through early diagnosis” noted Mrs. Evi Hatziandreou, MD, MPH, DrPH Dr. of Public Health, University of Harvard, Vice President of FairLife L.C.C., moderating the section dedicated to Prevention and Early Diagnosis. Mrs. Hatziandreou talked about the importance of prevention and expressed her optimism for the future, introducing two major advances in oncology: the accurate lung and breast cancer detection method via blood analysis with the use of artificial intelligence, and the identification of the genetic signature of tumors via reading biopsy slides with artificial intelligence.

For the status quo regarding the holistic screening in Greece, talked Mrs. Georgia Hardavella, MD, MSc, PhD Consultant, Chest Physician, “Sotiria” Athens Chest Diseases Hospital Chair, Lung Cancer Group, European Respiratory Society (ERS) Chair, Lung Cancer Group, Hellenic Thoracic Society, Secretary, European Board of Accreditation in Pulmonology (EBAP), who provided the comprehensive definition of lung cancer screening and presented the statistics of the disease in Greece. Referring to the already implemented screening programs – breast, colon, cervix – she stressed the imperative need for the inclusion of lung cancer as the 1^st cause of cancer death in Greece, in the National Prevention Plan. “In Greece guidelines and implementation procedures have been established, while multidisciplinary cooperation between three scientific associations and patients is ongoing, aiming at the creation of a specialised training program for health professionals.” highlighted Mrs. Hardavella.

Mrs. Ioanna Mitrouska, Pulmonologist, Director of the National Health System (NHS), Coordinator of the Smoking Cessation Reference Clinic, University Hospital of Heraklion, Crete, underscored that lung cancer is one of the most frequent causes of death worldwide, with smoking being the primary risk factor, as it interferes with normal cell development. She talked about the effects of smoking on pain and the need for a correct approach of the people who smoke. She mentioned that smoking cessation, even after being diagnosed, improves the quality of life, increases the life expectancy, reinforces the response to treatment and reduces the related side effects and the perioperative complications.

“Vaccines save lives, since infections are a major burden on society and the 3^rd cause of death worldwide”, stressed Mrs. Nikoletta Rovina,  Associate Professor in Pulmonary and Critical Care Medicine, Special Secretary of the Hellenic Thoracic Society (HTS), in her speech on infection prevention and the recommendations on vaccination for the vaccinations of patients with respiratory diseases and particular population groups with increased risk of serious disease and/or complications.

Mrs. Ioanna Tsiligianni, Associate Professor of General Practice and Public Health, Medical School, Faculty of Medicine, University of Crete talked about the value of Primary Health Care – which is highlighted by the medical community – with regard to an early diagnosis, underscoring that it is a central pillar of the health system, aiming at a holistic care for the patients and their families. She presented its ability to timely recognize risk factors and needs, as well as being effective in the diagnosis and the symptom detection. At the same time, she referred to the multiple gaps in Primary Health Care in Greece, the delays of cancer diagnoses and especially that of lung cancer as well as the need for patients’ awareness and mobilisation, beyond fear and nihilistic attitudes.

The discussion of the section focused on the questions raised by Mrs. Hatziandreou for the ability to respond quickly in the aforementioned challenges, pointing towards the existence of fear and delay in the prevention and the need to investigate ways to address them.

“The time is ripe for the implementation of screening” stated Mrs. Fofo Kalyva, Secretary General of Public Health, referring to the pilot implementation in 4 hospitals in the country but also in the difficulties of the implementation due to lack of mainly human resources as well as the reluctance and limited response rate of citizens in prevention programs. She expressed her optimism for the prominent role of the associations in fear management and in the change in culture of prevention.

Mr. Dimitris Paraskevis, BSc, MSc, PhD, Board Member of NPHO (EODY), Professor of Epidemiology & Preventive Medicine Dept. of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, talked about the challenge of addressing smoking addiction, in the need of smokers’ support and the personalised contact with patients for smoking cessation, following the diagnosis. He mentioned the large importance of PEKP and highlighted the cooperative role of EODY with stakeholders in the field of awareness on the outreach to vulnerable populations and the continuous concern of the entire society also towards prevention.

Mrs. Nikoletta Rovina, Associate Professor in Pulmonary and Critical Care Medicine, University of Athens, School of Medicine, Special Secretary of the Hellenic Thoracic Society (HTS), talked about the need for reinforcing the role of Primary Health Care in the State, the support of communication actions at the local authorities’ level and at remote areas in Greece and “investing” in the next generation as a catalyst for change. Mrs. Rovina expressed her trust in the patient associations for the awareness and mobilisation of the public that the Health System has difficulty in approaching.

“A screening program is not just an LDCT. It’s a program with a beginning, a middle and a continuation”, stated Ms. Elena Linardou MD, PhD, Medical Oncologist, Director of the 4th Oncology Clinic at “Metropolitan” Hospital, Chair of the ESMO Women for Oncology Committee, Member of the Board of Fairlife L.C.C. Ms Linandrou talked about the planning that is needed for a lung cancer screening program, considering it only concerns high risk groups and the combination of the program with timely referral to smoking cessation clinics. Lastly, she referred to the strictly necessary culture of prevention, lacking in Greece.

Mr. Kosmas Iliadis, MD, PhD, FETCS, Thoracic Surgeon, Director of Thoracic Surgery Dept. at HYGEIA Hospital, President of the Hellenic Society of Thoracic and Cardiovascular Surgeons (HCTSS) spoke about the joint efforts of thoracic surgeons to strengthen the concept of screening and the hope arising by its implementation. He talked about the need for specialised training to avoid the “acquittal” of nodes, the help that people who smoke need and the importance of informing society in a wider scope.

“The workplace is a space for actions that can yield results. Knowledge needs to be transferred to the social environment” stressed Ms. Rena Bardani, Chair of the Board of the Hellenic Institute of Occupational Health and Safety (EL.IN. Y.A.E.), that referred to the difficulty in making prevention a priority and way of life, despite its self-evident nature. She pointed out that prevention mindset requires time, awareness, continuous information and intensive efforts with actions addressed to young people.

Summarizing the most important parts of the discussion, Ms. Hatziandreou referred to the need for involvement of the State when it comes to prevention and the importance of

• the cooperation of the public and the private sectors
• the proper workplace within the context of Corporate Social Responsibility
• vaccination as an intervention that saves a huge amount of resources
• the “unconventional” citizens’ approach by the health system

 

New Age for Diagnostics for lung cancer: Staging, molecular biomarkers and artificial intelligence at the forefront

 With prevention and a holistic approach as foundations, lung cancer prognosis and treatments will considerably improve with the implementation of the 9^th edition of the TNM staging system for lung cancer, (2025). According to the speakers and commentators of Section A, artificial intelligence and molecular biomarkers enhance personalised medicine, a timely diagnosis with LDCT and immunotherapy increase survival and collaboration between specialists and the pharmaceutical industry promote innovation and equal access to patients.

For the perennial attempts to evaluate the extent of lung cancer spoke Mr. Ioannis Gkiozos, Pulmonologist, Scientific Associate at the National & Kapodistrian University of Athens, Oncology Unit, “Sotiria” General Hospital of Chest Diseases, Head of Task Force of Lung Cancer Group HTS, Member of Council of Regents, International Association for the Study of Lung Cancer, who referred to staging and the changes that are included in the 9^th the TNM staging system for lung cancer, (2025). “Staging is related to prognosis, and it offers the opportunity for more therapeutic manipulations and treatment for malignancy of the lung, aiming at the improvement of the patients’ quality of life and survival” summarised Mr. Gkiozos.

“We experience major changes in lung cancer treatment. With an eye on the future, we are going through an impressive present”, stated Mr. Nikos Koufos, MD, ECFMG, PhD, Pulmonologist, Scientific Director of Bronchoscopy and Interventional Pulmonology Unit, Metropolitan Hospital of Athens, who presented the process of bronchoscopic diagnosis and the modern lung periphery navigation tools and referred to the role of artificial intelligence and the contribution of AI programs in the improvement of bronchoscopic biopsy.

In her speech on the causes and prospects of molecular testing, Ms. Angeliki Saetta, Professor, Scientific Director of the Molecular Diagnostics Unit, 1st Dept. of Pathology, Medical School, National & Kapodistrian University of Athens, spoke about molecular testing, predictive biomarkers and personalized treatment as data for a new age. She referred to the different approaches and challenges of molecular testing and the importance of a database for the i interpretation of the massive parallel sequencing results. Ms. Saetta highlighted the key role of the pathologist and the Molecular Oncology Council as well as the importance of equal access and treatment of all patients.

Wishing that the conference would fulfil its scientific and social goal, Ms. Sophia Lambaki, Reader in Pulmonology – Lung Cancer, Pulmonology Clinic of Aristotle University of Thessaloniki (AUTH), “G. Papanikolaou” General Hospital, referred to the new potential that LDCT has offered to lung cancer early diagnosis and the improvement of patients’ life expectancy through immunotherapy. She talked about the importance of the new staging system, of the experience of the bronchoscopists for the collection of sufficient material and of timely information of the qualitative characteristics of NGS.

“Commitment and methodology to the goal against lung cancer in the pillars of prevention and early diagnosis” said Mr. Dimitris Lioubas, Thoracic surgeon, Attending Surgeon A’, General State Hospital of Nikaia – Piraeus “Agios Panteleimon”, who referred to the interventional developments that allow patients to return to their daily life soon and functionally and gave a positive note to the new staging system on behalf of the thoracic surgery community, wishing the entry of biomarkers into the daily medical practice for the benefit of all cancer patients.

Ms. Kyriaki Tavernaki, MD, MSc, PhD, Radiologist, Director of the Department of Medical Imaging and Interventional Radiology, “Sotiria” General Hospital for Chest Diseases, Secretary General of the Hellenic Radiological Society, referred to staging as the most decisive point in diagnosis, as it also concerns the prognosis. She spoke about the high level of radiologists in Greece and the modern imaging methods and technological tests that provide diagnostic accuracy and reliability in imaging tests, with clear findings as regards the stage of the disease.

Τhe lung as one of the first organs where Anatomic Pathology has incorporated molecular techniques for a more comprehensive evaluation of the cellular neoplastic ecosystems, was mentioned by Mr. Periklis Foukas, Professor, Medical School, National and Kapodistrian University of Athens, 2^nd Laboratory of Pathology, “Attikon” University Hospital, Special Secretary of the Hellenic Society of Pathology. Mr. Foukas noted that diagnostic biomarkers now include prognostic and predictive molecular biomarkers, which detect altered intracellular pathways and cancer cell interactions with the immune system. He spoke about the need for better tissue management to facilitate oncologists and stressed that artificial intelligence and digital anatomic pathology will contribute to the analysis of neoplastic diseases and the development of more effective treatment strategies in the future.

The contribution of the pharmaceutical industry, not only in the research and development of new targeted treatments but also in all stages of the lung cancer patient’s journey, was referred to by Mr. Christos Antonopoulos, MD, PhD, EMBA, Director of the Department of Oncology/Hematology, Board Member, AstraZeneca Pharmaceuticals Greece & Cyprus. Furthermore, he pointed out that at AstraZeneca we recognize the value of prevention and that is why we invest in awareness and better understanding of the disease. Finally, he referred to the role of biomarkers as a valuable tool for equal access to the appropriate therapeutic approach at the right time, confirming that Precision medicine offers multiple benefits for the patient while contributing to the sustainability of the health system.

Multidisciplinary approach, precision medicine, advances in thoracic surgery redefine the treatment of
early and locally advanced lung cancer

According to the speakers of Section B, lung cancer management requires multidisciplinary cooperation, personalized treatments based on molecular biomarkers and innovative approaches such as immunotherapy. Advances in anatomic pathology, interventional pulmonology and stereotactic radiosurgery improve diagnosis and treatment.

The main characteristics of a well-organized multidisciplinary council were analyzed by Mr. Ioannis Boukovinas, Medical Oncologist, Head of Oncology Unit, Bioclinic, Aristotle University of Thessaloniki, referring to the multiple benefits of MDT with ultimate financial benefit to the health system, the specialties involved and its primary objective, which is none other than to improve the care of cancer patients. He spoke about Molecular Oncology Council – as a development of tomorrow – with synchronous audio presentations and asynchronous discussions and the immediate need for a radical restructuring of the Oncology Council in Greece.

“Anatomic Pathology is the trunk of the tree of Medical Science” said Mr. Periklis Foukas, Professor, Medical School, National and Kapodistrian University of Athens, 2^nd Laboratory of Pathology, “Attikon” University Hospital, Special Secretary of the Hellenic Society of Pathology, speaking about the importance of biopsy samples approach, pathologic response after neoadjuvant treatment and   immunohistochemical biomarkers in lung cancer and the development of Digital Anatomic Pathology.

Mr. Grigoris Stratakos, MD, PhD, Professor of Resp. Medicine and Interventional Pulmonology, 1^st Respiratory Medicine Department, NK University of Athens, “Sotiria” Hospital, President of the European Association for Bronchology and Interventional Pulmonology (EABIP) highlighted the benefits of airway opening for the 20-25% of lung cancer patients with central airway obstruction. He spoke about the combined techniques and the different quality of life that interventional pulmonology now offers. “We want to produce a new generation of interventional pulmonologists who, in collaboration with other specialties, will provide a better tomorrow for lung cancer patients,” Mr. Stratakos said.

“All lung cancers have different biological behavior and molecular identity” stressed Mr. Konstantinos Papagiannopoulos, MD, MBChB, Mmed Thorax, FRCS, CTh, Honorary Senior Lecturer in Medical School of University Leeds in the UK, Director of the Thoracic Surgery Department in Euroclinic, 25^th President of the European Society of Thoracic Surgeons, referring to the need for different treatment for each patient. He talked about the developments of thoracic surgery, the strengthening of the role, and the characteristics of a modern thoracic surgeon who is responsible for ensuring the patients’ quality of life. “There is no reason to add days to the patient’s life if we cannot add life to his days” added Mr. Papagiannopoulos.

For the treatment algorithms for early and locally advanced disease talked Mr. Vangelis Fergadis, Medical Oncologist, Registrar B, Metaxa Cancer Hospital, who referred to epidemiology, risk factors, incidence and mortality of lung cancer. Mr. Fergadis presented treatment options and treatment combinations depending on the stage of the disease, the existence of biomarkers, before and after the surgical procedure, for both NSCLC and SCLC.

 “Today, 1 in 3 patients, and especially after COVID-19, are diagnosed at an operable stage” emphasized Mr. Ioannis Mountzios, Medical Oncologist, Director of the 4th Oncology Department and Clinical Trials Unit, Henry Dunant Hospital, Founder of Oncolife Network, talking about perioperative treatment strategy and new, innovative treatments that tend to turn lung cancer into a chronic disease. Mr. Mountzios presented the benefits and challenges of immunotherapy before and after surgery, the role of treatment in the early stages, and its significant efficacy at advanced lung cancer.

“In recent years lung cancer is the disease that has given the best results with the help of molecular biology, pharmacology, and science as a whole”, stated Mr. Nektarios Alevizopoulos, Medical Oncologist, Evaggelismos General Hospital, who referred to the benefits of personalized treatment due to the identification of molecular footprint, the need for implementation of the Oncology Board right after the diagnosis and during the patient’s course of treatment. Mr. Alevizopoulos characterized the identification of oncogenic mutations, target receptors that guarantee hope and efficacy for lung cancer patients, as good news or common ground consensus.

The importance and the role of lung cancer specialist nurse as a “navigator” of patients analyzed Mr. Dimitris Papageorgiou, Assistant Professor, University of Peloponnese, Head Nurse Oncology Unit, Euroclinic Athens, President of Hellenic Oncology Nursing Society. Mr. Papageorgiou referred to the exceptional collaboration and the vision of FairLife L.C.C. and talked about the importance of coverage of the different and complicated needs of patients and caregivers that occur after the diagnosis and during the course of treatment.

Mr.  Eleftherios Eleftheriadis, Pathologist, Vice President, Hellenic Society of Pathology, talked about the great value of Anatomic Pathology but also about the challenges regarding the quality of laboratory testing and the small number of accredited laboratories. He referred to the utmost importance of Oncology Councils; however, he highlighted the organization and coordination issues in their practical implementation.

The extremely important role of radiotherapy in lung cancer treatment highlighted Mr. Georgios Pissakas, MD, PhD, Radiation Oncologist, Head of Radiation Oncology Dpt., “Alexandra” General Hospital, Former President of the Hellenic Society of Radiation Oncology. He referred to the implementation of stereotactic radiosurgery in case of unfeasible surgery in both the early stage and the oligometastatic disease. Mr. Pissakas emphasized the great importance of early detection through screening for the disease to be largely curable.

Mr. Levon Toufektzian, Thoracic Surgery Registrar, Director of the Thoracic Surgery Clinic, Athens Medical Center, referred to the surgical procedure as the current most effective lung cancer treatment, including the modern, less interventional approaches. He talked about the benefits of segmentectomies for small lesions on a case-by-case basis and the benefits of immunotherapy, pointing out that the doctor’s constant improvement, the priority on patients’ safety, and the efficacy of treatments must be the core values of medical profession.

“Lung cancer treatment is not a game for one, it is a decision by all scientists” stressed Ms. Andriani Harpidou, Director of the Clinical Trials Department, 3rd Internal Medicine Clinic and Laboratory, National and Kapodistrian University of Athens, “Sotiria” Hospital, who referred to the 3 pillars of the disease treatment: early diagnosis-screening, Oncology Councils and timely biomarker testing from the initial biopsy for all patients.

Mr. Petros Christopoulos, MD, PhD Medical Oncologist – Hematologist, Professor of Medicine, Heidelberg University referred to the radical shift of the treatment of patients with early lung cancer with the initiation of targeted treatments and immunotherapy. Therefore, he highlighted the need for conducting molecular testing, clinical studies, and Oncology Council. “For Greek patients, these major developments at an international level could become tangible with the coordinated efforts of the oncology community with the pharmaceutical companies” stressed Mr. Christopoulos.

Mrs. Vasiliki Mytilinaiou, Caregiver, Business Operations Manager, spoke about the caregiver’s multi-faceted role, and shared her personal story as a caregiver of her husband who is suffering from lung cancer. Mrs. Mytilinaiou stressed the importance of choosing a knowledgeable doctor, the significance of information and awareness, psychosocial support, and of seeking a second medical opinion. “With knowledge, data and alternatives in our hands, we must move forward. The patient must be a participant in the process”.

Ms. Angeliki Aggeli, Chief Portfolio Value Officer, Roche Hellas, talked about the new trends that redefine health systems with regard to patients: patients’ empowerment and their active participation in decision making, focusing on quality of life and personalized care. At the same time, she referred to specific proposals for harnessing innovation such as the removal of certain criteria in the evaluation process of new pharmaceutical formulations (HTA) and the expansion of the OIKOTHEN program and other programs aiming at decentralised health care. Ms. Aggeli emphasised the need for adequate funding and addressing rebates imposed by the State.

 

Clinical studies are the backbone of medicine, the main challenges being insufficient funding, lack of information, inequalities of access and reduced patient participation in Greece

Clinical studies are the foundation of medicine, with challenges such as low patient recruitment and inequality of access in Greece requiring immediate action. Speakers in Section C referred to the new European regulation as positive development, while the international collaboration and investments were considered vital. The need to foster a culture of research and the attraction of more studies to Greece was underscored.

“Clinical studies are the backbone of medicine” stressed Mr. Giorgos Kapetanakis, President of Hellenic Cancer Federation (ELLOK), moderating the section dedicated to the importance of clinical studies. Mr. Kapetanakis spoke about the declining rate of studies in Europe, presenting the global landscape of clinical studies and referred to the problem of patient recruitment, to inequalities of access to clinical research, and he highlighted the importance of attracting clinical studies in Greece.

 “80% of clinical studies are either delayed or not completed due to problems in patient recruitment” stated Stefanos Tarazis, MD, PhD, Head of Clinical Trials Dept. EOF, Professor of University of Athens, Gastrenterologist, referring to the landscape around clinical trials worldwide, while also highlighting this increasing trend in Greece. He presented in detail the new European regulation (CTR 536/2014) on clinical trials to ensure transparency, cooperation, and their strengthening in the European Union. Lastly, he spoke about the Clinical Trials Information System (CTIS), informing the audience about ongoing clinical studies.

“Although clinical studies in oncology have increased, 50% are conducted across the Atlantic” pointed out Ms. Helena Linardou, MD, PhD, Medical Oncologist, Director of the 4th Oncology Clinic, “Metropolitan” Hospital, Chair of the ESMO Women for Oncology Committee, BoD Member, FairLife L.C.C., stressing that Eastern Europe falls behind in clinical studies, with Greece currently running 26 phase 3 studies on lung cancer. She spoke about the benefits of clinical research – patient active role, free and early access to innovation, options at every stage of the disease – and the challenges of participating in clinical studies – ignorance, fear, myths – highlighting the inequalities in clinical studies on cancer and the lack of clinical research culture.

Ms. Amanda Psyrri, MD, PhD, FACP, Professor of Medical Oncology, National & Kapodistrian University of Athens, Head of Oncology Department, Attikon University Hospital, analysed the 3 pillars of research – basic, translational, and clinical research – emphasizing the significant impact of Greek research at an international level. Ms. Psyrri furthermore spoke about the challenges faced by academic research in Greece and internationally, regarding insufficient funding and reduced patient participation, and about the significance of international collaboration for the progress and the development of research.

The biggest challenges for the production of new drugs are enormous costs and lengthy process, as Mr. Theodoros Tsichritzis, Medical Lead Oncology for Greece, Cyprus and Malta, MSD Greece, mentioned. Mr. Tsichritzis spoke about the contribution of the pharmaceutical industry to clinical research with high investments, with a 60% of global spending for the development of new drugs and sponsorships that support all clinical studies on lung cancer in Greece. Lastly, he talked about the low number of clinical studies conducted in Greece in 2024 (78 studies on lung cancer), compared to countries of similar size.

 

Immunotherapy and Targeted Therapies: A revolution in metastatic lung cancer and hope for patients with rare mutations

The management of metastatic lung cancer through the initiation of immunotherapy and targeted therapies engaged the Section D speakers, who characterized personalized treatment and participation in clinical trials as crucial to progress, aiming at better prognosis and quality of life.

“We hope we have found the “Achilles’ heel” of lung cancer”, said in his speech on immunotherapy Dr. Michalis Karamouzis, Medical Oncologist, Professor, School of Medicine, National & Kapodistrian University of Athens, who highlighted the great change that the initiation of immunotherapy has brought upon the treatment of metastatic disease. He referred to the therapeutic approach of patients who develop resistance to immunotherapy and to the potential benefits of its early application before conventional treatment methods.

“The mutation in the ALK gene affects only 2% of patients, but in fact it is about >75,000 patients annually with NSCLC, mainly women, non-smokers, of younger age” emphasized Mr. Theofanis Floros, Director, 5th Oncology Department, Metropolitan General Hospital Deputy Director, Oncology Department, NIMTS Former Research Faculty, University of Pittsburgh School of Medicine, USA, who referred to the 5 ALK protein inhibitors, to the best results of the 3^rd generation inhibitor, and to the importance of the correct choice of medication for each patient.

 In his speech regarding the EGFR biomarker, Mr. Ioannis Mountzios, Medical Oncologist, Director of the 4th Oncology Department and Clinical Trials Unit, Henry Dunant Hospital, Founder of Oncolife Network, referred to the epidemiology of the EGFR mutation involving exons 19, 20 and 21, molecular inhibitors of the mutation and resistance mechanisms that impose the development of 2^nd and 3^rd generation inhibitors. He spoke about the improved prognosis and survival of patients with mutations and emphasized the importance of awareness of side effects that can significantly affect the patients’ quality of life.

Referring to the “least traveled” paths of the ROS1 – NTRK – RET – BRAF – KRAS – HER2 biomarkers, Mr. George Lainakis, MD, MSc, Medical Oncologist, Deputy Director, 4th Oncology Dept., Metropolitan Hospital, presented the updated landscape and the response rates on approved molecules that have entered the lung cancer treatment algorithm with driver mutations. He emphasized the ever-increasing importance of targeted treatment at the front line, especially for patients with rare mutations, whom he encouraged to participate in clinical trials to derive safer conclusions on these mutations.

 

The Cancer Patient as “A Holistic Phenomenon”. Prioritizing Comprehensive Oncology Care, Psychosocial Support, and Palliative Care.

 Speakers in Section E unanimously agreed on the value of the holistic management of lung cancer patients, through a multidisciplinary approach, palliative care, psychosocial support, and intervention in physical pain.

“Pain is a disease with its own rights,” stated Dr. Athina Vadalouka, MD, PhD, FIPP, Assoc. Prof. of Anesthesia, Pain Management and Palliative Care, Director of Pain and Palliative Care Center of Athens Medical Center, PARH.SY.A Past President, discussing the health-related “suffering”, the interventional techniques for pain management, and the critical role of multidimensional treatment and timely palliative care for the survival time of lung cancer patients.

Ms. Zoe Grammatoglou, President of the Athens Association of Cancer Patients “KEFI”, highlighted the lack of progress in palliative care in Greece, expressing her concern on the delay in the organized integration of palliative care into the health system, on the lack of political will and the overwhelming burden placed on patient associations and organizations to fill gaps in patient support.

“The epitome of holistic management for lung cancer patients is a multidisciplinary approach,” noted Dr. Dimitra Kanaloupiti, Medical Oncologist, Director of the 4th Oncology Clinic, “IASO” Hospital, who referred the benefits of Holistic Medicine, speaking about treating the patient as a “whole” and health management in all dimensions, in the light of the Patient-Driven Care model, where patients have an active role in their course of treatment. Lastly, she separately mentioned the aspect of the stigma associated with lung cancer and related to survival, mainly due to delayed seeking medical attention.

“The cancer patient is a holistic phenomenon from the outset, and we must form a concentric circle of care around them,” stressed Dr. Paris Kosmidis, Medical Oncologist, Head, 2nd Medical Oncology Dpt., HYGEIA Hospital, Athens, underscoring the role of new treatments in the change of the landscape around lung cancer, with the improvement of both patients’ survival and quality of life. She wondered whether the scientific community and society are prepared to meet the rapid advancements in medicine and urged all stakeholders and citizens to be mobilized for the benefit of vulnerable patients, beyond the actions of the State.

“The voices and needs of patients and their caregivers must be heard,” emphasized Ms. Ifigeneia Koutri, FairLife L.C.C. Volunteer, Caregiver, Clinical Psychologist, PhD in Social and Clinical Psychology, Aristotle University of Thessaloniki (AUTH), speaking about her personal experience as a caregiver for her late husband. She underscored the need for awareness on prevention, holistic and patient-centered approach, and addressing inequalities and discrimination caused by cancer.

Dr. Anna Papageorgiou, PhD, Clinical Dietitian-Nutritionist, Medical School, National & Kapodistrian University of Athens, Specialist in Physical Education & Sports Science, Scientific Director of Health Promotion Programs “EVROSTIA”, discussed the modern tools offered by nutrition science in combination with physical exercise, to prevent sarcopenia and cachexia in cancer patients and maintain muscle mass. “Training on comprehensive oncology care, alternative therapies, and the implementation of lifestyle medicine is required,” Dr. Papageorgiou stated.

“Nothing do we have more in common, nothing connects us more than human mental suffering,” reflected Ms. Triantafyllia Tabaliaki, BS, MS, Psychologist – Psychoanalytic Psychotherapist, Group Analyst who shared a therapeutic session with the audience to emphasize the importance of focusing on the mental state of cancer patients, who are often struggle with guilt, profound existential questions, personal anxieties, and the stigma of the disease.

Ms. Kiki Tsakaldimi, Mountaineer, FairLife Ambassador, FairLife L.C.C. Board Member, referred to the multiple benefits of exercise and connecting with nature for both physical and mental health. “When our body is strong, it can better combat illness, and pain levels decrease. Moderate exercise must enter everyone’s daily lives, and we must motivate ourselves and our loved ones to participate in wellness activities as a means for both prevention and treatment,” miss Tsakaldimi stated.

 

The key role of pharmaceutical industry in patient-centered innovation. Collaborations and national action plan; the pillars to improve the quality of life and the health system.

 

Mr. Giorgos Karahalios, MD, Neurologist, Medical Affairs Director, Genesis Pharma, referred to the immense progress of Precision Medicine, and its therapeutic benefit. He stressed the need for the health system to proceed to the necessary cuts and reforms, so that, on the one hand, our society can meet the cost of this progress and, on the other hand, the patients in our country can have access to innovation. He mentioned that the primary consideration of the pharmaceutical industry is to gear the research efforts towards offering patients the best possible quality of life, and the primary consideration of the State is to support innovation, ensuring the patients’ timely and equal access to cutting-edge treatments in our country.

Mr. Christos Martakos, Governmental & Industrial Relations Director, Pharmaserve-Lilly S.A.C.I., President Market Access Hellenic Society (MAHS), expressed his serious concern on the practices of the State with regard to the introduction of innovation in Greece, referring to rebate, clawback of pharmaceutical expenditure to the State, lack of mobilization for clinical trials and inequalities created by the emergency introduction of personalized treatments. “In Greece, innovation and pharmaceutical policy are unrelated terms”, Mr. Martakos concluded.

Mr. Aristidis Nikolaou, MD, MSc Pulmonologist, Medical Manager Oncology Lung, AstraZeneca, referred to the benefit of the Multidisciplinary Oncology Council (MDT) and the holistic approach of lung cancer patients, emphasizing the power of collaboration of all specialties involved and the pharmaceutical industry, which supports scientific programs and clinical studies that enhance multidisciplinary communication and training of all specialties for the efficacy of new drugs.

The benefit to the economic system from investing in vaccines discussed Mr. Andreas Roussidis, Ph.D. Country Medical Director, GSK (Greece), emphasizing the contribution of the pandemic in highlighting prevention and the importance of vaccination against infectious diseases. “Lung cancer prevention and early diagnosis have a key role, as they not only save lives but also contribute to the improvement of their quality. By investing in preventive measures and regular medical check-ups, we essentially invest in a healthier and more optimistic future for everyone” stated Mr. Roussidis.

Mr. Theodoros Tsichritzis, Medical Lead Oncology for Greece, Cyprus and Malta, MSD Greece, referred to the unfavorable environment that has been shaped in Greece regarding patients’ equal access to innovative treatments, as well as the contribution of the pharmaceutical industry through proposals, ideas, solutions, significant initiatives, and a strong clinical impact on lung cancer.

Critical was described by Mr. Sofoklis Hanos, Communications & Patient Advocacy Manager, BMS Greece, the State’s commitment to draw up an action plan for the holistic management of cancer in Greece, for the benefit of both the patients and the National Health System. Mr. Hanos emphasized the patients’ quality of the life, which is linked to a 25% increase in the chances of survival from lung cancer, a 15-20% reduction in pharmaceutical and treatment cost, and a 20-30% annual decrease in hospitalizations, readmissions and indirect costs savings for patients.

 

 

FairLife Lung Cancer Care 

 “FairLife Lung Cancer Care ”  is the first and only non-profit social organization in Greece engaged exclusively in lung cancer – the 1^st cause of cancer death both in our country and worldwide. The organization’s mission is to inform and raise awareness for lung cancer prevention, and to offer holistic support to patients and their families throughout their journey with the disease.

To support our mission:

• We inform about prevention, early diagnosis, and screening, aiming at reducing mortality.
• We raise awareness of the value of integrated molecular testing.
• We provide psychosocial support to patients, caregivers, and family members.
• We encourage and educate patients, bodies, and the public on the importance of clinical studies and access to new, innovative treatments.
• We work towards combatting smoking-related stigma.
• We engage the younger generation and the public about the positive impact of a clean environment on lung health. To this end, we promote environmental awareness, sustainability actions, and sustainable practices in the context of tackling climate change.

FairLife – Lung Cancer Care was founded in memory of Simon Bell, 57, who lost his battle with lung cancer in August 2020.

 

FairLife L.C.C.:

18 Napoleontos Zerva Str.,16675, Glyfada, Greece

Tel: 210 8980180

Information Line – FairLine 111 57

Email: info@fairlifelcc.com

WEBSITE | YOUTUBE | FACEBOOK | LIKEDIN | INSTAGRAM | TWITTER | TIK TOK